Announcements Trials
Browse Landscape

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Malnutrition 2

Interventions

Rituximab 29Surveys and Questionnaires 25Blood Specimen Collection 17Gene Expression Profiling 15Flow Cytometry 14Polymerase Chain Reaction 13Amplified Fragment Length Polymorphism Analysis 13Microarray Analysis 11Observation 10Interviews as Topic 10Psychiatric Rehabilitation 9Lenalidomide 9Immunohistochemistry 9Cytogenetic Analysis 9obinutuzumab 8Watchful Waiting 8Therapeutics 8ibrutinib 7Drug Therapy 7Cyclophosphamide 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6fludarabine 5In Situ Hybridization, Fluorescence 5Immunologic Techniques 5Data Collection 5Brentuximab Vedotin 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × fish oil triglycerides × Lymphoid × Clear all
NCT06274788 2025-09-05

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Fresenius Kabi

Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Malnutrition, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04807478 2022-08-04

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

Fresenius Kabi

Withdrawn
LymphoidOther hematologic neoplasm

Malnutrition, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡